✉news HealthMedicine first seen 13 h ago, last 6 h ago, peak #18

Insilico Medicine's AI-designed cancer drug shows 40% response rate

Original: Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

Insilico Medicine presented clinical results for ISM6331, a pan-TEAD inhibitor designed using generative AI, at the ESMO 2026 congress. In heavily pretreated mesothelioma patients, the drug achieved a 40% objective response rate at a 130 mg dose. The findings are being noted as an early sign that AI-discovered cancer therapies can deliver meaningful results in hard-to-treat tumors.

Why now: The data is new evidence that generative AI-designed drugs can produce clinically meaningful results in difficult cancers.

Insilico MedicineISM6331ESMOmesothelioma

Open on news →

Evidence

• Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026 · EurekAlert!
• Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026 · EurekAlert!

API: https://socialmediatrends-api.osmike.com/v1/trends/3786667